Core Insights - The OCEANIC-STROKE Phase III trial results are being presented at ISC 2026 in New Orleans, indicating significant advancements in secondary stroke prevention [1][2] - Bayer's team includes key figures in clinical development and neurology, highlighting the importance of collaboration in addressing unmet medical needs [2] Group 1: Unmet Medical Needs - There remains a significant unmet medical need in the secondary stroke prevention setting, which is a focus of Bayer's ongoing research efforts [2] Group 2: Trial Data and Implications - Ashkan Shoamanesh, a principal investigator of the OCEANIC-STROKE trial, will present the trial data, which is expected to be favorable [2] - The data from the trial may provide insights into potential treatment options for secondary stroke prevention [2] Group 3: Health Economic Challenges - Jan Voss will discuss health economic challenges in the secondary stroke setting and how asundexian could potentially address these issues in the future [2]